Literature DB >> 7923245

Increased proliferation of a human breast carcinoma cell line by recombinant interleukin-2.

M Katano1, T Matsuo, T Morisaki, K Naito, F Nagumo, E Kubota, M Nakamura, T Hisatsugu, J Tadano.   

Abstract

Two adenocarcinoma cell lines, Breast M25-SF and Breast M, were established from tumor tissue resected surgically from a patient with breast cancer. One, Breast M25-SF, expresses interleukin-2 receptor (IL-2R) on the cell surface and the other, Breast M does not. The effects of recombinant interleukin-2 (rIL-2) on the proliferation of these cell lines were investigated. The growth of Breast M25-SF was significantly promoted by rIL-2 ranging from 1.25 U/ml to 640 U/ml. Anti-CD25 (Tac) antibody significantly blocked the growth enhancement of Breast M25-SF by rIL-2. Breast M, however, did not respond to rIL-2. To confirm more directly the promotion of Breast M25-SF growth by rIL-2, cloning of IL-2 responders from parent Breast M25-SF cells was carried out by limiting dilution without feeder cells in 96-well microplates. No colony formation was found in 24 wells without rIL-2. Eleven, 13 and 6 clones were established from groups of 24 wells containing rIL-2 at 200, 20 and 2 U/ml respectively. All of the clones expressed IL-2R and respond to rIL-2. By using a sensitive polymerase chain reaction technique, we demonstrated that Breast M25-SF but not Breast M expressed IL-2 mRNA, and IL-2 secretion from Breast M25-SF but not Breast M was also confirmed by radioimmunoassay. These findings suggest a role for IL-2 in autocrine support of Breast M25-SF growth. IL-2 may play an important role in the growth control of breast carcinoma cells.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7923245     DOI: 10.1007/bf01533381

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  24 in total

1.  Interleukin 2 mediates the inhibition of oligodendrocyte progenitor cell proliferation in vitro.

Authors:  R P Saneto; A Altman; R L Knobler; H M Johnson; J de Vellis
Journal:  Proc Natl Acad Sci U S A       Date:  1986-12       Impact factor: 11.205

2.  Purification and characterization of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  K Kato; T Yamada; K Kawahara; H Onda; T Asano; H Sugino; A Kakinuma
Journal:  Biochem Biophys Res Commun       Date:  1985-07-31       Impact factor: 3.575

3.  AIDS Kaposi sarcoma-derived cells produce and respond to interleukin 6.

Authors:  S A Miles; A R Rezai; J F Salazar-González; M Vander Meyden; R H Stevens; D M Logan; R T Mitsuyasu; T Taga; T Hirano; T Kishimoto
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

4.  Interleukin-2 differentially affects the proliferation of a hormone-dependent and a hormone-independent human breast cancer cell line in vitro and in vivo.

Authors:  G F Paciotti; L Tamarkin
Journal:  Anticancer Res       Date:  1988 Nov-Dec       Impact factor: 2.480

5.  Transfection of interleukin 2 gene into human melanoma cells augments cellular immune response.

Authors:  A Uchiyama; D S Hoon; T Morisaki; Y Kaneda; D H Yuzuki; D L Morton
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

6.  Expression of the interleukin-2 receptor on human fibroblasts and its biological significance.

Authors:  S Plaisance; E Rubinstein; A Alileche; Y Sahraoui; P Krief; Y Augery-Bourget; C Jasmin; H Suarez; B Azzarone
Journal:  Int Immunol       Date:  1992-07       Impact factor: 4.823

7.  Biological activity of recombinant human interleukin-2 produced in Escherichia coli.

Authors:  S A Rosenberg; E A Grimm; M McGrogan; M Doyle; E Kawasaki; K Koths; D F Mark
Journal:  Science       Date:  1984-03-30       Impact factor: 47.728

8.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

9.  Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

Authors:  J J Mulé; S Shu; S L Schwarz; S A Rosenberg
Journal:  Science       Date:  1984-09-28       Impact factor: 47.728

10.  Structure and expression of a cloned cDNA for human interleukin-2.

Authors:  T Taniguchi; H Matsui; T Fujita; C Takaoka; N Kashima; R Yoshimoto; J Hamuro
Journal:  Nature       Date:  1983 Mar 24-30       Impact factor: 49.962

View more
  5 in total

1.  Influence of cytokines, monoclonal antibodies and chemotherapeutic drugs on epithelial cell adhesion molecule (EpCAM) and LewisY antigen expression.

Authors:  D Flieger; A S Hoff; T Sauerbruch; I G Schmidt-Wolf
Journal:  Clin Exp Immunol       Date:  2001-01       Impact factor: 4.330

2.  Local Interleukin-2 Immunotherapy of Breast Cancer: Benefit and Risk in a Spontaneous Mouse Model.

Authors:  Svetlana G Semushina; Dmitry A Aronov; Ekaterina V Moiseeva
Journal:  Pathol Oncol Res       Date:  2018-03-06       Impact factor: 3.201

3.  Sensitive detection of pathway perturbations in cancers.

Authors:  Corban G Rivera; Brett M Tyler; T M Murali
Journal:  BMC Bioinformatics       Date:  2012-03-21       Impact factor: 3.169

4.  Interleukin-2 and its receptor complex (alpha, beta and gamma chains) in in situ and infiltrative human breast cancer: an immunohistochemical comparative study.

Authors:  Ignacio García-Tuñón; Mónica Ricote; Antonio Ruiz; Benito Fraile; Ricardo Paniagua; Mar Royuela
Journal:  Breast Cancer Res       Date:  2003-10-22       Impact factor: 6.466

5.  Applications of Bayesian network models in predicting types of hematological malignancies.

Authors:  Rupesh Agrahari; Amir Foroushani; T Roderick Docking; Linda Chang; Gerben Duns; Monika Hudoba; Aly Karsan; Habil Zare
Journal:  Sci Rep       Date:  2018-05-03       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.